Literature DB >> 28407036

The clinical impact of an EML4-ALK variant on survival following crizotinib treatment in patients with advanced ALK-rearranged non-small-cell lung cancer.

S Seo1, C G Woo2, D H Lee1, J Choi3.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28407036     DOI: 10.1093/annonc/mdx185

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  2 in total

1.  Targeting EML4-ALK gene fusion variant 3 in thyroid cancer.

Authors:  Mehtap Derya Aydemirli; Jaap D H van Eendenburg; Tom van Wezel; Jan Oosting; Willem E Corver; Ellen Kapiteijn; Hans Morreau
Journal:  Endocr Relat Cancer       Date:  2021-05-11       Impact factor: 5.678

2.  GeneFuse: detection and visualization of target gene fusions from DNA sequencing data.

Authors:  Shifu Chen; Ming Liu; Tanxiao Huang; Wenting Liao; Mingyan Xu; Jia Gu
Journal:  Int J Biol Sci       Date:  2018-05-22       Impact factor: 6.580

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.